Cargando…
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807388/ https://www.ncbi.nlm.nih.gov/pubmed/34408266 http://dx.doi.org/10.1038/s41375-021-01386-z |
| _version_ | 1784643655888273408 |
|---|---|
| author | Damaschin, Carla Goergen, Helen Kreissl, Stefanie Plütschow, Annette Breywisch, Frank Mathas, Stephan Meissner, Julia Sökler, Martin Topp, Max S. Vucinic, Vladan Zimmermann, Andreas von Tresckow, Bastian Fuchs, Michael Engert, Andreas Borchmann, Peter Eichenauer, Dennis A. |
| author_facet | Damaschin, Carla Goergen, Helen Kreissl, Stefanie Plütschow, Annette Breywisch, Frank Mathas, Stephan Meissner, Julia Sökler, Martin Topp, Max S. Vucinic, Vladan Zimmermann, Andreas von Tresckow, Bastian Fuchs, Michael Engert, Andreas Borchmann, Peter Eichenauer, Dennis A. |
| author_sort | Damaschin, Carla |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8807388 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88073882022-02-07 Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group Damaschin, Carla Goergen, Helen Kreissl, Stefanie Plütschow, Annette Breywisch, Frank Mathas, Stephan Meissner, Julia Sökler, Martin Topp, Max S. Vucinic, Vladan Zimmermann, Andreas von Tresckow, Bastian Fuchs, Michael Engert, Andreas Borchmann, Peter Eichenauer, Dennis A. Leukemia Letter Nature Publishing Group UK 2021-08-18 2022 /pmc/articles/PMC8807388/ /pubmed/34408266 http://dx.doi.org/10.1038/s41375-021-01386-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Damaschin, Carla Goergen, Helen Kreissl, Stefanie Plütschow, Annette Breywisch, Frank Mathas, Stephan Meissner, Julia Sökler, Martin Topp, Max S. Vucinic, Vladan Zimmermann, Andreas von Tresckow, Bastian Fuchs, Michael Engert, Andreas Borchmann, Peter Eichenauer, Dennis A. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group |
| title | Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group |
| title_full | Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group |
| title_fullStr | Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group |
| title_full_unstemmed | Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group |
| title_short | Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group |
| title_sort | brentuximab vedotin-containing escalated beacopp variants for newly diagnosed advanced-stage classical hodgkin lymphoma: follow-up analysis of a randomized phase ii study from the german hodgkin study group |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807388/ https://www.ncbi.nlm.nih.gov/pubmed/34408266 http://dx.doi.org/10.1038/s41375-021-01386-z |
| work_keys_str_mv | AT damaschincarla brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT goergenhelen brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT kreisslstefanie brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT plutschowannette brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT breywischfrank brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT mathasstephan brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT meissnerjulia brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT soklermartin brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT toppmaxs brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT vucinicvladan brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT zimmermannandreas brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT vontresckowbastian brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT fuchsmichael brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT engertandreas brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT borchmannpeter brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup AT eichenauerdennisa brentuximabvedotincontainingescalatedbeacoppvariantsfornewlydiagnosedadvancedstageclassicalhodgkinlymphomafollowupanalysisofarandomizedphaseiistudyfromthegermanhodgkinstudygroup |